Achilles Therapeutics Company

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Connections from

Last Funding Type: Grant
Total Funding: 212991704.0
Last Funding Date: 2022-07-21
Funding Status: IPO
Employee Number: 1-10
Estimated Revenue: $10M to $50M
Technology: Medical BioTech
Investors Number: 15.0
Founded Date: 2016-05-01
Headquarters: London, England, United Kingdom
Industry: Medical BioTech